Produktdetaljer
ISBN
9781420037937
Publisert
2015
Utgave
1. utgave
Utgiver
Vendor
CRC Press
Språk
Product language
Engelsk
Format
Product format
Digital bok
Forfatter
More than 20 billion dollars worth of biopharmaceuticals are scheduled
to go off-patent by 2006. Given the strong political impetus and the
development of technological tools that can answer the questions
regulatory authorities may raise, it is inevitable that the FDA and
EMEA will allow biogeneric or biosimilar products. Even with all the
regulato
Les mer
Regulatory, Manufacturing, Testing, and Patent Issues
Produktdetaljer
ISBN
9781420037937
Publisert
2015
Utgave
1. utgave
Utgiver
Vendor
CRC Press
Språk
Product language
Engelsk
Format
Product format
Digital bok
Forfatter